osu-2s

OSU-2S is a synthetic small-molecule derivative of FTY720 (fingolimod) designed to retain potent anticancer activity but without the immunosuppressive effects associated with the parent compound[1][2][9]. Unlike FTY720, OSU-2S does not interact with sphingosine-1-phosphate (S1P) receptors, thus avoiding unwanted immune suppression[2][9]. Its primary mechanisms of action include activation of protein kinase C delta (PKCδ) signaling, induction of reactive oxygen species (ROS), PKC-dependent phosphorylation of the tumor suppressor SHP1, protein phosphatase 2A (PP2A) activation, and downregulation of oncogenes such as TCL1A[1][7]. OSU-2S exhibits strong preclinical cytotoxicity in various hematological malignancies (chronic lymphocytic leukemia [CLL], mantle cell lymphoma [MCL], acute lymphoblastic leukemia [ALL]) and in solid tumors such as hepatocellular carcinoma (HCC)[1][2][3]. In addition, it shows synergistic effects when combined with other agents such as sorafenib in HCC and milatuzumab in MCL[2][5].